For healthcare professionals only

  1. Research
  2. Availability of...
  3. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13
CCBYNC Open access
Research

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

BMJ 2017; 359 doi: https://doi.org/10.1136/bmj.j4530 (Published 04 October 2017) Cite this as: BMJ 2017;359:j4530

Data supplement

Related articles

FeatureCancer drugs: high price, uncertain value
EditorialDo cancer drugs improve survival or quality of life?
CommentaryThe current model has failed
Should we accept higher p values than 0.05 for new cancer drugs?

See more

Cited by...

  • Healing an ailing pharmaceutical system: prescription for reform for United States and Canada
  • Removing the blindfold on medicines pricing
  • Outcomes for cancer drugs approved in Europe
  • Cancer drugs: high price, uncertain value
  • Do cancer drugs improve survival or quality of life?
Back to top